1.5% Glycine Irrigation is a sterile, nonpyrogenic aqueous solution suitable for
urologic irrigation. This solution is slightly hypotonic. 1.5% Glycine Irrigation is
indicated as an irrigant during transurethral prostatic or bladder surgery.
1.5% Glycine Irrigation USP is nontoxic, nonhemolytic, not sticky, and has a
refractive index close to that of water. These properties make it useful as a urologic
irrigating fluid, particularly during transurethral surgical procedures where the
irrigant may be absorbed through cut venous sinuses.
Systemically absorbed glycine is primarily metabolized by transamination to
serine, and by deamination to ammonia which is normally removed by its
conversion to urea. A portion of the absorbed glycine is excreted by the kidneys.

As required for irrigation.
1.5% Glycine Irrigation should be administered only by the appropriate
transurethral urologic instrumentation.
It has been reported that absorption is significantly increased if the container is
higher than 60 cm (24") above the patient.
This drug product should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit.

Solutions for urologic irrigation must be used with caution in patients with severe
cardiopulmonary or renal dysfunction.
The amount of fluid absorbed during a transurethral resection is a function of the
volume and hydrostatic pressure of the irrigant used, the number and size of
venous sinuses opened, and the duration of the procedure. Since irrigating fluids
used during transurethral prostatectomy have been demonstrated to enter the
systemic circulation in relatively large volumes, any irrigation solution must be
regarded as a systemic drug.
Absorption of large amounts of fluids containing glycine and the resultant osmotic
diuresis may significantly affect cardiopulmonary and renal dynamics. Absorption
of large amounts of irrigating solution can also result in pronounced hyponatremia
and water intoxication.
After opening container, the contents should be used promptly to minimize the
possibility of bacterial growth or pyrogen formation.
Discard unused portion of irrigating solution since it contains no preservative.
Cardiovascular status, especially in patients with cardiac disease, should be

carefully determined before and during transurethral resection of the prostate when
using 1.5% Glycine Irrigation as an irrigant. The fluid absorbed into the systemic
circulation via severed prostatic veins may produce significant extracellular fluid
expansion and lead to fulminating congestive heart failure.
Shift of sodium-free intracellular fluid into the extracellular compartment
following systemic absorption of 1.5% Glycine Irrigation may lower serum sodium
concentration and aggravate preexisting hyponatremia.
Excessive loss of water and electrolytes may lead to serious imbalances. Sustained
diuresis from transurethral irrigation with 1.5% Glycine Irrigation may obscure and
intensify inadequate hydration or hypovolemia.
Care should be exercised if impaired liver function is known or suspected. Under
such conditions, ammonia resulting from the metabolism of glycine may
accumulate in the blood. Use only if solution is clear and container and seal are
intact.

N/A

Animal reproduction studies have not been conducted with 1.5% Glycine

Irrigation,. It is not known whether 1.5% Glycine Irrigation, can cause fetal harm
when administered to a pregnant woman or can affect reproductive capacity. 1.5%
Glycine Irrigation, should be given to a pregnant woman only if clearly needed.

This medicine no influence on the ability to drive and use machines.

Adverse reactions may include fluid and electrolyte disorders such as acidosis,
electrolyte loss, marked diuresis, urinary retention, edema and dehydration;
cardiovascular/pulmonary disorders such as pulmonary congestion, hypotension,
tachycardia, angina-like pain and thrombophlebitis; other possible reactions
include visual disturbances, convulsions, nausea, vomiting, diarrhea, vertigo and
urticaria.
Literature includes reports on hyponatremia, hyperammonemia, transient
blindness, coma (immediate or delayed), and digitalis toxicity in digitalized
patients.
If an adverse reaction occurs, discontinue the irrigant and reevaluate the clinical
status of the patient.

To report any side effect(s):
Saudi Arabia:
The National Pharmacovigilance Centre (NPC):
Fax: +966-11-205-7662
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa
Other GCC States:
Please contact the relevant competent authority

In the event of overhydration or solute overload, re-evaluate the patient and
institute appropriate corrective measures. See WARNINGS, PRECAUTIONS and
ADVERSE REACTIONS.

Helps trigger the release of oxygen to the energy requiring cell-making process;
Important in the manufacturing of hormones responsible for a strong immune
system.

Absorption
Absorbed from the small intestine via an active transport mechanism.
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Hepatic

Not applicable

Water for injection

Not applicable

Store below 30°C for size: 3000 ml plastic bag. Store below 25°C for size: 2000
plastic bag.

Plastic Polyethylene Bottle -NPVC-Bag supplied in: 2000 ml, 3000 ml.

Do not use unless the solution is clear and the container undamaged. Remove the
cap/port seal and connect by clamping to the administration set.